Preparation for stimulating vital activity of biological object and method for producing the preparation

FIELD: medicine; medical engineering.

SUBSTANCE: preparation comprises carrier treated with electromagnetic field. The carrier is a substance selected from a group composed of pharmaceutically permissible powder or pill substrate having crystalline substance in the amount of at least 23% by mass, physiologic fluid or liquid crystals. The carrier is treated with electromagnetic field using frequencies of 0.01-9.0 kHz, 10.0-100.0 kHz or 0.5-10.0 MHz during 0.5-60 min. Method involves producing a preparation comprising carrier being a substance selected from a group composed of pharmaceutically permissible powder or pill substrate having crystalline substance in the amount of at least 23% by mass, physiologic fluid or liquid crystals. The carrier is treated with electromagnetic field of abovementioned frequency during 0.5-60 min. Optimum treatment time is selected depending on carrier nature.

EFFECT: stable properties during one year; enhanced effectiveness in agricultural production processes; encouraging future application in medicine.

13 cl, 2 tbl

 

The invention relates to the field of Biophysics. veterinary medicine, in particular to the development of a drug that activates the activity of biological objects of different levels of organization (animal or human body, microbiological culture, plants, seeds etc) and the method of obtaining a product, the end result of which may be the elimination of an adverse condition of a biological object or activation of its life, the stimulation of the metabolism or growth.

In living organisms there are numerous physical and biochemical reactions and interactions, strictly coordinated in time and space. This entire procedure is sent to the permanent preservation and reproduction of organisms in certain external conditions. Any biological object or body is a unified system in which all its elements, as well as cells, tissues and organs interact. The interaction between the different elements of a biological object or parts of a living organism and the environment due largely biological energy fields, which in addition to the main neurohumoral interactions, is mutual control between these elements.

Known methods of registration ELEH the electromagnetic fields and radiation on special media in the moment of recording in different phase States, undertaken to assess the status of biological objects, which, for example, are produced in the optical (GB No. 515866), infrared or radio frequency (DE No. 3605104) bands on the film and other sensitive fields of the media.

Known methods of exposure to electromagnetic fields and radiation in a wide frequency range for the correction of the state of biological objects, for example, stimulation of certain functions of man (US No. 5095901, US 5617856, 1997, US 6032063, 2000, EN 2154508, 2000), activation of plant productivity (SU # 1665952) or yeast cells (SU # 1592328).

There are also known methods of exposure on various biological objects for complex organisms (EN 2105575, 1998, EN 2121334, 1998), and disorganized, for example, microorganisms (EN 2146540, 2000). However, most of the known impacts on biological objects by using large and small structures, the effect of which is constantly changing and is often accompanied by hidden or not sufficiently studied side effects.

A close analogue to the claimed invention is the development in which the described method of bioresonance therapy (patent RU 2065297, 1996), which used the influence on the organism of biological electromagnetic fields Ave is childbirth.

However, in any well-known design not solved the problem of stability effects on the biological object using universalizing, portable, optionally labeled, means of enhancing the activity of a biological object capable of adequately comparable effects of electromagnetic fields on various living organisms.

The present invention is the creation of a universal portable product for increasing life of a biological object using a physiological carrier, can be marked, to work in a wide range of electromagnetic fields (EMF) and to stably retain the original properties for a long time.

The technical result is achieved by the fact that created the drug for increasing life of a biological object that contains the media, activated by processing electromagnetic field (EMF) using a circuit that is able to produce EMFs, while the carrier is a substance selected from the group of pharmaceutically acceptable powder or tablet base, containing not less than 23% by weight of a crystalline substance, a physiological fluid or liquid crystals, and processing of media held within 0.5-60.0 minutes EMF with a frequency of 0.01 Hz - 9.0 kHz, 10.0-100.0 chili 0.5 to 10.0 MHz. As a powder or tablet basics contains a mixture of not less than 2 substances selected from the group of talc, starch, dextran, polietilenglikol, starch syrup, magnesium oxide, colloidal silicon dioxide, cellulose or its derivatives, lactose or its derivatives, optionally may contain various excipients for tableting, pharmaceutically acceptable dyes for marking the degree of activation of the media EMF. As crystalline substances contains inorganic salt of potassium, magnesium, calcium or sodium, sucrose, glucose, fructose, maltose, lactose, rhamnose, ribose, dextrose, or a mixture. As a physiological fluid contains a physiological sodium chloride solution or nutrient medium, diluted with drinking water in the ratio 1:(5-10)selected from the group: a solution of ringer, Wednesday Needle, Board-Zhang, Levintal, Fidls, Zeissler, serum agar or meat-peptone broth.

As the cellulose derivatives, the preparation may contain cellulose acetate, acetylcellulose and its sodium salt of the cellulose acetate. acetylcellulose and its sodium salt, carboxymethyl cellulose (CMC) and its sodium salt, methylcellulose, microcrystalline cellulose (MCC), oxypropylation, oksipropilmetiltselljuloza, as well as additional accessories the x substances can be used alginic acid and its sodium salt, Aerosil, water, wax, glycol, dextrin, gelatin, kaolin, acid wine. the lemon acid, stearic acid and its calcium and magnesium salts, magnesium carbonate, mannitol, vaseline oil, vegetable oil, wheat flour, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), natural gums, tuberosum, sorbitol, tween-80, titanium dioxide, tropeolin 0, flavorsome, cerulean, ethylcellulose, shellac and other substances.

As crystalline substances the product contains various inorganic pharmaceutically acceptable salt, such as salt, potassium, magnesium, calcium, sodium, sugar, for example sucrose, glucose, fructose, maltose, lactose, rhamnose, ribose, dextrose, or a mixture.

As a physiological fluid, the drug contains a physiological sodium chloride solution or nutrient medium selected from the group: ringer's solution, Wednesday Needle, Board-Zhang, Levintal, Fidls, Zeissler, serum agar or meat-peptone broth. Liquid Foundation preparation should be diluted with drinking water in the ratio 1:(5-10)as diluted environment longer retain acquired after activation EMFs new properties, if the native activated environment is guaranteed to retain the property for 10 months, then diluted with water 5-10 times 12 months or longer.

The product obtained on solid media (p is Raskova or tablet base, the latter can be extruded into pellets and activated EMF stably retains its acquired properties 5 years, liquid preparations stored in sealed vials in a sterilized condition 12 months.

The invention is illustrated by the following winners of the new drug.

EXAMPLE 1: Preparation of activated EMF, powder media.

To prepare the drug took a powder consisting of a mixture of pharmaceutically acceptable ingredients: talc, sodium lactate, sodium chloride is in the following ratio (% wt.):

sodium chloride - 25,0

sodium lactate - 10,0

talc - rest.

The powder was placed inside the outline that is able to produce EMFs, such as electromagnetic (EM) circuit described in the patent of Russian Federation № 2070406, and within a 6.0 min was irradiated EMF with a frequency of 10.0 to 100.0 kHz. The drug at room conditions can save EM properties within 12 months.

EXAMPLE 2. The drug, activated EMF, tablet media. To prepare the drug used the pill that contains potassium chloride, potato starch, excipients: gelatin, polietilenglikol, iron oxide, dye sunset yellow in the following ratio of components (weight%):

Potassium chloride - 30,0

The glycol - 10,0

Other excipients - 5,0

Starch - rest.

The finished tablet weight of 0.6 to 10 g placed inside the outline, as in example 1, specify the frequency of 0.5-10 M Hz and incubated for 10-30 minutes. Shelf life 5 years guaranteed at 25 months.

EXAMPLE 3. The drug, activated EMF, physiological solution. Several vials containing physiological solution of sodium chloride, is placed inside the outline that is able to produce EMFs, at a frequency of 0.01 Hz and 9.0 kHz at 60-70 C, the solution is sterilized and sealed in a vial. The drug is stable for 12 months.

EXAMPLE 4. The drug, activated EMF, diluted with nutrient medium. Medium Needle diluted with drinking water in the ratio 1:7, poured into ampoules of 10 ml, sterilized ampules were soldered. Sealed ampoule was placed inside the outline that is able to produce EMFs. Kept at a frequency of 0.01 Hz and 9.0 kHz for 2 minutes. The drug stores acquired after activation EMFs new properties in the next 12 months.

Another object of the invention is a method of producing drug for increasing life of a biological object.

The technical result is achieved by the fact that the developed method of producing drug for increasing life of a biological object by EMF exposure to the media, the media use a substance selected from the group of pharmaceutically acceptable powder or tablet base, the soda is containing not less than 23% by weight of a crystalline substance, physiological fluid or liquid crystals, and the influence exercised by the EMF with a frequency of 0.01 Hz and 9.0 kHz, 10,0-100,0 kHz or 0.5 to 10.0 MHz for 0.5 to 60 minutes. As a powder or tablet basics use a mixture of not less than 2 substances selected from the group of talc, starch, dextran, starch syrup, magnesium oxide, colloidal silicon dioxide, cellulose or its derivatives, lactose or its derivatives.

As crystalline substances used inorganic salt of potassium, magnesium, calcium or sodium, sucrose, glucose, fructose, maltose, lactose, rhamnose, ribose, dextrose, or a mixture. Optionally use the excipients for tableting.

To mark the degree of activation of the media EMF using pharmaceutically acceptable dyes.

For example, to indicate the degree of activation of the solid carrier preformed on the basis of the EMF with a frequency of 0.01 Hz and 9.0 kHz, you can use the medium without dye, and the degree of activation of the preformed carrier EMF with a frequency of 10.0 to 100.0 kHz, you can add the dye, giving a yellow color, and for the EMF with a frequency of 0.5 to 10.0 MHz - red color.

As a physiological fluid using a physiological sodium chloride solution or nutrient medium, diluted with water in the ratio 1:(5-10), and the medium is chosen from the group: a solution of the Ring is RA, Wednesday Needle, Board-Zhang, Levintal, Fidls, Zeissler, serum agar or meat-peptone broth. When using powder or tablet basics, effects of EMFs perform optimally within the 6.0-30.0 minutes. When using liquid crystals EMF exposure perform optimally within 1.0 to 5.0 minutes. Using physiological fluids, exposure to EMFs perform optimally within 0.5 to 2.0 minutes

Thus obtained the drugs used for enhancing the life of the organism, as evidenced by the following examples.

Example 5. The study was performed in experimental conditions in industrial microorganisms used in agriculture as producers of protein, amino acids and other forage substances used in animal husbandry, and food production associated with the fermentation process. In particular, testing of the preparation described in example 3. conducted on the following strains - producers of glutamic acid: Mycrococcus glutamicus, Brevibacterium flavum Br.aminogenes, Br.saccharalyticum. When their cultivation under standard conditions was added 1 ml per 10 ml of culture medium, the control used the drug without activating his EMI and conducted cultivation without making the drug. In the experimental group, the yield of the final product was 17-25% higher than in the control.

Example 6. In the experiments conducted in the North-Caucasian scientific research Institute of livestock breeding of the RAAS (Krasnodar, Russia), was established directional change of metabolism for industrial poultry (ducks, geese), which as a veterinary drug feed consumed the product described in example 1. Comparative analysis showed a statistically significant increase in the productivity of animals in the experimental group compared to control-treated powder carrier is not activated EMF and the group not receiving the drug, the estimated increase was in the range of 35-40% and above.

Example 7. The study was performed in healthy volunteers: 6 men aged from 23 to 54 years and 8 women aged 25 to 56 years.

The basis of the test of the invention for the volunteers properly known in physiology regulation on primary metabolism, which characterizes the amount of energy that is released in the body when increasing life, for example, by changing the volume of oxygen consumed and allocated carbon dioxide. The resulting energy is taken for heat energy and expressed in kilocalories (for example, Experimental physiology. TRANS. from English. edited Bandry, M.: Mir, 1974, 122-127).

Sitting quietly in patients was determined basal metabolism by the graphic region is ation of changes in the amounts of oxygen consumed and allocated carbon dioxide in a closed breathing system with the use of a spirograph "Metatest-2". The source level was men from 36,5 j/m2with to 42.2 j/m2with, and women from 30,1 to 41.8 j/m2C. Patients received the drug, described in example 2, as well as other drugs obtained by the claimed method, containing a crystalline substance sucrose, fructose or ribose at different degrees of activation of drugs EMF. For control used the same drugs without activating them EMFs. All patients significantly increased the level of basal metabolic rate, on average 5-8% compared to control, and subjectively, patients improved health and mood.

Additional tests of the drugs obtained by the claimed method, on the expiry of 12 months from the date of their preparation showed that their biological activity and EM properties are stored in 99.7% of cases.

Thus, the present invention is a drug for increasing life of a biological object, is highly effective, universalizable, stable during storage and can be used for agricultural production, but also has a significant perspective for medical purposes.

Additional examples

EXAMPLE 8: Preparation of activated EMF, powder media.

To prepare the drug took a tablet-based, consisting of a mixture of FA is matemticas acceptable components: starch, sodium lactate, sodium chloride, microcrystalline cellulose in the following ratio (% wt.):

sodium chloride - 25,0

sodium lactate - 10,0

microcrystalline cellulose - 2,0

starch - rest.

The powder was placed inside a standard electromagnetic (EM) circuit capable of EMFs, are described, for example in the patent of Russian Federation № 2070406, and for 50 min was irradiated EMF with a frequency of 100 kHz. The drug at room conditions can save EM properties within 12 months.

EXAMPLE 9. The drug, activated EMF, physiological solutions. Several vials containing saline solution, placed inside the outline that is able to produce EMFs in the frequency range 0.01 Hz to 9.0 kHz. The solution is sterilized and sealed in a vial. The drug retains the properties guaranteed not less than 12 months. Table 1 shows the test results on the preservation of EM properties of various physiological solutions at different values of frequency and time of exposure to EMFs.

Table 1
Wednesday Needle: water=1:5 (n=10)ringer's solution: water=1:6 (n=10)environment Board-Zhang: water=1:8 (n=10)environment Levintal: water=1:7 (n=10)environment Faints: water=1:10 (n=10)
0.01 Hz100.0 Hz0,5 kHz9,0 kHz
120±5100±560±0.5 s45±0.5 s30±0.5 s
13,0±0,05 months.14,0±0,05 months.14,0±0,05 months.13,0±0,05 months.13,0±0,05 months.
Reliability for all dimensions p<0,05

EXAMPLE 10. The drug, activated EMFs on liquid crystals. As the liquid crystals used cholesterolaemia, cholesterylester or cholesterolemia. Table 2 presents the results for the conservation of EM properties of these substances for a long time: at least one year.

Table 2
View of a liquid crystalCholesterolaemia,CholesterylesterCholesteryl-oleate(n=10) for each type
Frequency0.5 MHz5.0 MHz10.0 MHz
The exposure time60±5160±5300±5
The duration of the preservation of EM properties14±0,05 months.20±0,05 months.25±0,05 months
Reliability for all dimensions p<0,05

Preparations are presented in table 2, was used as the activating means for the fattening of geese and ducks on farms in the Rostov region in 2001-2003, Cholesteryl-oleate was added to the feed in an amount of 0.2% by weight of the total feed for 2 months in raising poultry for meat and fat. In comparison with feeding feed average daily gain in geese was 276,5±5.7 g (n=450 heads), for ducks 184,6±7,8 g (n=650 heads). The reliability of all measurements p<0,05.

1. Drug for increasing life of a biological object that contains the media treated the electromagnetic field (EMF) using a circuit that is able to produce EMFs, characterized in that the carrier is a substance selected from the group of pharmaceutically acceptable powder or tablet base, containing not less than 23% by weight of a crystalline substance, a physiological fluid or liquid crystals, and processing of media held the EMF with a frequency of 0.01 Hz and 9.0 kHz, 10,0-100,0 kHz or 0.5 to 10.0 MHz for 0.5-60 minutes

2. The preparation according to claim 1, characterized in that, as a powder or tablet basics contains a mixture of not less than 2 substances selected from the group of talc, starch, dextran, starch syrup, colloidal silicon dioxide, cellulose or its derivatives, lactose or proizvodnye.

3. The preparation according to claim 1, characterized in that as crystalline substances contains inorganic salt of potassium, magnesium, calcium or sodium, sucrose, glucose, fructose, maltose or a mixture.

4. The preparation according to claim 2 or 3, characterized in that optionally may contain excipients for tableting, pharmaceutically acceptable dyes.

5. The preparation according to claim 1, characterized in that as a physiological fluid contains a physiological sodium chloride solution or nutrient medium, diluted with drinking water in the ratio 1:(5-10)selected from the group: Wednesday Needle, ringer's solution, and environment Board-Zhang, Levintal, Faints.

6. The method of producing drug for increasing life of a biological object by EMF exposure on a carrier, characterized in that as the carrier using a substance selected from the group of pharmaceutically acceptable powder or tablet base, containing not less than 23% by weight of a crystalline substance, a physiological fluid or liquid crystals, and the influence exercised by the EMF with a frequency of 0.01 Hz and 9.0 kHz, 10,0-100,0 kHz or 0.5 to 10.0 MHz for 0.5-60 minutes

7. The method according to claim 6, characterized in that, as a powder or tablet basics use a mixture of not less than 2 substances selected from the group of talc, starch, dextran, starch is Naya syrup, magnesium oxide, iron oxide, colloidal silicon dioxide, cellulose or its derivatives, lactose or its derivatives.

8. The method according to claim 6, characterized in that the crystalline quality of the substances used inorganic salt of potassium, magnesium, calcium or sodium, sucrose, glucose, fructose, maltose, lactose or a mixture.

9. The method according to claim 7 or 8, characterized in that it additionally used excipients for tableting, pharmaceutically acceptable dyes.

10. The method according to claim 6, characterized in that as a physiological fluid using a physiological sodium chloride solution or nutrient medium, diluted with water in the ratio 1:(5-10), and the medium is chosen from the group of ringer's solution, Wednesday Needle, Board-Zhang, Levintal, Faints.

11. The method according to claim 6, characterized in that when using powder or tablet basics, effects of EMFs perform optimally within the 6.0-30,0 minutes

12. The method according to claim 6, characterized in that when using liquid crystals, EMF exposure perform optimally during 1,0-5,0 minutes

13. The method according to claim 6, characterized in that when using a physiological fluid EMF exposure perform optimally within 0.5 to 2.0 minutes



 

Same patents:

FIELD: medicine, gastroenterology, pharmacy.

SUBSTANCE: invention describes solid pharmaceutical compositions used in treatment of gastroenteric disorders. The composition comprises omeprazole as a proton pump inhibitor wherein at least part of drug is not covered by an enterosoluble envelope and sodium hydrocarbonate as a buffering agent. The composition is made as a chewing tablet. By the second variant the composition comprises omeprazole that is partially is not covered by an enterosoluble envelope, sodium hydrocarbonate as a buffering agent and at least one disintegrating agent and/or lubricant. In oral administration in a patient of indicated pharmaceutical compositions the effective amount of omeprazole in absorbed directly by patient stomach for immediate and effective treatment of disorders associated with gastric acid. New medicinal formulations of omeprazole are suitable for preparing and provide its rapid absorption and availability of the omeprazole preparation for a definite group of patients that are unable to swallow solid medicinal formulations.

EFFECT: improved and valuable medicinal and pharmaceutical properties of formulations.

19 cl, 4 dwg, 5 tbl, 13 ex

FIELD: methods of preparation of pharmaceutical composition.

SUBSTANCE: pharmaceutical composition has to be solid amorphous homogenous dispersion of medicinal preparation. The composition increase content of polymer due to switching of high pressure sprayer and dissipating plate on to improve flow of drying gas and to increase sizes of drying chamber which improves time of drying.

EFFECT: improved characteristics of fluidity of dispersions; improved efficiency of collection of particles.

15 cl, 9 tbl, 7 dwg, 3 ex

FIELD: medicine, in particular dry azithromicine mixtures to produce azithromicine pellets by direct pressing.

SUBSTANCE: claimed formulation contains non-dehydrated azithromicine selected from group containing B, D, E, F, G, H, J, M, N, O, P, Q, R forms or mixtures thereof, and at least one pharmaceutically acceptable carrier. Pellet containing non-dehydrated azithromicine mixture and at least one pharmaceutically acceptable carrier, as well as azithromicine pellet obtained by providing of dry mixture containing non-granulated azithromicine A and at least one pharmaceutically acceptable carrier, followed by direct pressing said mixture also are disclosed.

EFFECT: direct pressable azithromicine-containing formulations; azithromicine pellets having acceptable hardness and frangibility.

14 cl, 6 ex, 1 dwg, 6 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition used for stabilization of homeostasis and arresting pathological processes in the body. Invention proposes a pharmaceutical composition as powder with particles size from 250 to 400 mcm comprising the following components by the first variant, wt.-%: carbon, 10.01-53.02; oxygen, 30.10-53.10; potassium, 0.26-1.99, and calcium, 0.20-31.37, and comprising the following components by the second variant, wt.-%: calcium, 0.35-31.20; carbon, 10.99-50.21; oxygen, 34.55-51.03; sulfur, 0.73-14.81, and phosphorus, 0.08-3.30. Invention provides compensation of trace elements unbalance that causes and accompanies many diseases, possibility for stabilization of trace element homeostasis and arresting pathological processes of different etiology.

EFFECT: improved and valuable medicinal properties of composition.

12 cl, 13 ex

FIELD: pharmaceutical technology, pharmacy.

SUBSTANCE: invention relates to a method for preparing submicron particles of water-insoluble or difficultly water-soluble organic pharmaceutical substance. Method involves dissolving this substance in the first water-mixing solvent, mixing the prepared solution with the second solvent for making pre-suspension and homogenization of prepared pre-suspension or by its ultrasonic oscillation. Method provides preparing particles of size less 2 mcm.

EFFECT: improved preparing method.

32 cl, 17 dwg, 18 ex

FIELD: pharmacy.

SUBSTANCE: invention relates to a granulated pharmaceutical composition comprising granulated material and erythritol. Granulated material comprises a medicinal substance of unpleasant taste and wax. Also, invention relates to a pharmaceutical product for oral using that comprises the indicated granulated composition. The composition masks unpleasant taste of a medicinal agent and provides good feeling in oral using. The granulated composition can be swallowed easily by elderly humans, children and patients suffering with dysphagia. Except for, the product is useful for administration by using a tube.

EFFECT: improved and valuable properties of composition.

15 cl, 5 tbl, 6 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes using xenogenous oligo-and/or polyribonucleotides, namely total RNA and tRNA, as an active component of external anhydrous medicinal agent for a single treatment of skin tumor relapse (for example, basalioma) or infections caused by herpes virus and the corresponding method for treatment. The claimed external anhydrous medicinal agents decline effectively relapses of indicated diseases after a single intake.

EFFECT: enhanced effectiveness and valuable medicinal properties of agents.

5 cl, 2 ex

FIELD: medicine, oncology.

SUBSTANCE: invention relates to method for malignant tumor treatment (including cancer, sarcoma, melanocytoma) in human by ectasceine ET743 intravenous infusion in dose of 500-1650 mug/m2 of surface are; to similar treatment by combination of ET743 with antiemetic agent; as well as to relative composite preparation. Method of present invention provides clinical amelioration in subject suffering from progressive or metastasing cancer and improves treatment effectiveness of diseases being progressed after known chemotherapy.

EFFECT: new effective method for cancer treatment; drug with good acceptability.

31 cl, 3 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method suggested should be implemented due to conserving velvet antlers after cutting, purification and reducing up to particles' size of not more than 7x7 mm to be then applied into vacuum drying drum-type chamber to create there discharging of 0.95-1.0 atm. It is necessary to supply water at 50-60 C into heat casing of drying chamber, treatment process lasts for 14-18 h at oscillating rotation of drying chamber at frequency being 10 rot./min, moreover, the product should not be heated above 37 C, at achieving the moisture of product preparing being 3-5% one should rotate drying chamber at frequency of not less than 50 rot./min and reducing should be fulfilled with grinding metal bodies as either spheroidal or cylindrical form which are present in drying chamber up to dispersity of not more than 0.1 mcm to be then packed airproof for better storage. The innovation is oriented to increase bioavailability and bioactivity of powder obtained due to decreasing the temperature for conserving velvet antlers up to 37 C.

EFFECT: higher efficiency.

1 tbl

FIELD: pharmaceutics.

SUBSTANCE: the suggested powder consists of crystals of one component amiphostin, the length of crystalline granule corresponds to 300-700 mcm at the content of 1-3 molecule of crystalline water. In method for obtaining amiphostin powder for injections one should apply the process of vacuum drying. The innovation provides resistance of the product obtained, the crystals obtained have got moderate length and acceptable mobility without any reduction.

EFFECT: higher efficiency of application.

6 cl, 5 dwg, 13 ex, 3 tbl

FIELD: medicine, oncology, pharmacy.

SUBSTANCE: invention relates to agents used in treatment of tumors and can be used in treatment of different tumor neoplasms. The proposed agent possessing an antitumor activity comprises methylene glycol as an active component and a saline solution as an inert solvent in the following ratio of components, wt.-%: calcium chloride (CaCl2), 0.018-0.021; potassium chloride (KCl), 0.018-0.021; methylene glycol, 0.1-1.0, and water, the balance. The optimal curative daily dose is 20-40 mcl/1 kg of body weight. Invention provides achievement of the stable clinical effect, reducing treatment time and decreasing the toxic effect.

EFFECT: valuable medicinal property of agent.

2 cl, 5 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to agents used in treatment of joint diseases in the form of injection solutions. The proposed agent comprises the following components, wt.-%: saccharide - chondroitin sulfate, 0.5-20.0; preserving agent, 0.1-2.0; non-ionogenic surfactant, in particular, monoester of oleic acid and polyoxyethylated sorbinate, 1.0-5.0, and water, the balance. Invention provides the high bioavailability and the diffusion rate of active substance into the joint zone.

EFFECT: valuable medicinal properties of agent.

2 cl, 3 tbl, 6 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a liquid pharmaceutical composition comprising pegilated erythropoietin as a conjugate in pharmaceutically acceptable buffer at pH from 5.5 to 7.0 and optionally one or some pharmaceutically acceptable excipients. Proposed composition is used in treatment and prophylaxis of diseases associated with erythropoiesis injury. The advantage of invention involves enhancing stability of the preparation.

EFFECT: improved and valuable property of preparation.

59 cl, 4 tbl, 11 dwg, 13 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a cycloferon-containing medicinal agent used in prophylaxis and treatment of influenza and acute respiratory diseases, herpetic infection, chronic viral hepatitis B and C and prophylaxis of oncological diseases. Agent comprises a physiological solution in the following ratio of components: 10-29 - 10-2 mg of cycloferon in 1 ml of physiological solution. Also, invention relates to a method for preparing this medicinal agent. Proposed medicinal agent enhances antiviral and antitumor activity of natural killers by 1.8-fold, not less.

EFFECT: improved preparing and using method, valuable medicinal properties of agent.

7 cl, 1 dwg, 19 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to new medicinal agents for parenteral using based on an antidepressant agent pirlindole salts. Agent comprises 2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole (pirlindole) sulfonate salts as an active substance, such as methane sulfonate or benzene sulfonate. The composition for intravenous or intramuscular injection comprises additionally citric acid and water taken in the definite ratios. Invention provides preparing an agent possessing good tolerance, low toxicity and resistance in storage.

EFFECT: improved and valuable medicinal and pharmaceutical properties of agent.

2 cl, 1 tbl, 4 ex

FIELD: pharmacy.

SUBSTANCE: invention proposes a liquid pharmaceutical composition containing nicotine in any form for administration into the mouth cavity and alkalinized with a buffer and/or by regulation of pH value. Administration is carried out preferably by spraying and the most preferably by sublingual spraying. Also, invention relates to a method for preparing the indicated composition. Use of indicated composition in therapy, such as therapy for treatment of addiction to tobacco.

EFFECT: valuable pharmaceutical properties of composition.

51 cl, 11 ex

FIELD: medicine.

SUBSTANCE: invention relates to microemulsion preconcentrate comprising active ingredient, oil, surfactant and hydrophilic solvent selected from group containing propylene glycol diacetate, propylene glycol acetate and salts thereof. Microemulsion preconcentrate optionally contains as active ingredient not only hydrophobic compounds but also hydrophilic compounds and proteins.

EFFECT: microemulsion preconcentrate of improved quality.

6 cl, 6 tbl, 3 dwg, 14 ex

FIELD: medicine.

SUBSTANCE: claimed viscoelastic based on 1.5-2.5 % methylcellulose contains additionally 0.0125-0.025 % dipivephrin hydrochloride solution and 0.0005-0.01 % of benzalconium chloride as stabilizer.

EFFECT: viscoelastic for prevention of eye tissues during intraocular interferences.

2 ex

FIELD: pharmaceutical chemistry.

SUBSTANCE: invention deals with creating pharmaceutical compositions containing bile acids and methods of treatment using these compositions. For this purpose, invention provides transparent aqueous solution containing bile acid or its compounds, polysaccharide, and water. Amounts of the two formers are selected so that they remain in solution at all values within selected pH range. Administration of such a composition increases level of enterohepatic bile acid in body, including blood, and also increases absorption of bile acid. Addition of various drug to composition allows effective treatment of corresponding diseases.

EFFECT: improved transportation to body tissues of bile acids both as individual therapeutic agents and as drug forms.

47 cl, 11 dwg, 16 tbl, 18 ex

FIELD: medicine, ophthalmology, chemico-pharmaceutical industry.

SUBSTANCE: the suggested pharmaceutical composition is indicated for local application and contains an inhibitor angiotensin converting enzyme as an active substance and target additions, moreover, the content of active substance corresponds to about 1-20 mg/ml. The composition suggested could be designed as eye drops, spay, gels, solution for local injections. As target additions one should apply water that contains a buffer agent, an isotonic mixtures, a conservant and a prolongator. Additionally, this composition contains preparations chosen out of the following groups: antibiotics, macro- and microelements, vitamins, adrenoblocking agents. The innovation provides anti-ischemic action, improves reparative processes and accelerates the processes of healing.

EFFECT: higher efficiency.

3 cl, 7 ex

FIELD: medicine, possible use, in particular, during reflex therapy.

SUBSTANCE: thermo-electric module consists of alternating circular branches, made, respectively, from semiconductor of n-type and p-type, serially connected in electrical circuit by means of commutation plates, electric connection of branches is realized by contact: n-type branch -commutation plate - p-type branch - commutation plate, n-type branch, etc. Semiconductor branches and commutation plates have circular shape. Commutation plates are provided with eight square leaves. Leaves are bent at direct angle to commutation plane so, that if one of them is bent to one side, then next one is bent to other side with forming of a polyhedron. Onto leaves of commutation plates, electro-isolating heat-conductive cover is applied (or example, lacquer). Device is provided with handle, which connects to thermo-electric battery through bearings. Power current to thermo-electric battery is fed along handle of device through electric brushes.

EFFECT: increased reliability of device, simplified construction of device.

2 dwg

Up!